Equities

Kodiak Sciences Inc

Kodiak Sciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.51
  • Today's Change-0.07 / -2.71%
  • Shares traded114.67k
  • 1 Year change+20.10%
  • Beta2.3361
Data delayed at least 15 minutes, as of Sep 20 2024 18:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments286479732
Total Receivables, Net------
Total Inventory------
Prepaid expenses3.807.073.30
Other current assets, total------
Total current assets289486735
Property, plant & equipment, net175116108
Goodwill, net------
Intangibles, net------
Long term investments----0
Note receivable - long term------
Other long term assets8.725955
Total assets479667904
LIABILITIES
Accounts payable149.1312
Accrued expenses284352
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities425265
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total172178176
Total liabilities214230241
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,4181,3301,222
Retained earnings (accumulated deficit)(1153)(892)(558)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(1.31)0
Total equity266436663
Total liabilities & shareholders' equity479667904
Total common shares outstanding535252
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.